Pooled phase 1/2 data support 10 mg/kg every 3 weeks as the provisional pivotal dose of the PD-1/VEGF bispecific antibody cesalatamig in previously treated NSCLC.
Commentary|Articles|March 31, 2025
The Long-Term Impact of COVID-19 on Oncology Care: A Five-Year Retrospective
Author(s)Courtney Flaherty
Fact checked by: Caroline Seymour
Experts across specialties reflect on the long-term effects of COVID-19 on several aspects of cancer care.
Advertisement
Advertisement
Five years after the onset of the COVID-19 pandemic, the oncology field continues to grapple with its repercussions. From fundamental shifts in patient management, including the introduction of telemedicine, to trial disruptions and workforce challenges, the pandemic has reshaped every aspect of oncology care. Although some of these adaptations offer unique benefits, others require strategic solutions, and the oncology community must continue to adapt and innovate to ensure optimal patient outcomes.
Related to this article
A dual antigen–targeted T-cell engager doublet produced durable PSA responses in late-line metastatic castration-resistant prostate cancer.
Invikafusp alfa plus sacituzumab govitecan produced responses and disease control in metastatic TNBC and HR-positive/HER2-negative breast cancer.
The top 5 OncLive TV videos of the week cover insights in NSCLC, gynecologic cancers, CRC, multiple myeloma, and NMIBC.
A post hoc analysis of SPEARHEAD-1 found that MAGE-A4 H-score was independently tied to response and progression-free survival, whereas baseline tumor burden was tied to overall survival.
The IL-12–expressing self-replicating mRNA STX-001 showed a favorable therapeutic window at 100 µg, with regression in both injected and non-injected lesions.
Most of the survival time accrued with RP1 plus nivolumab in the IGNYTE trial was spent in good health among patients with advanced melanoma after anti–PD-1 therapy.
VET3-TGI produced responses in injected and non-injected lesions without dose-limiting toxicities in the phase 1/1b STEALTH-001 trial.
Advertisement
Advertisement